Stay updated on MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to a Phase II clinical trial for a combination of drugs as a potential treatment for unresectable or metastatic melanoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:42:26.000Z thumbnail image
  6. Check
    20 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    55%
    Check dated 2024-05-22T21:13:07.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:24:58.000Z thumbnail image

Stay in the know with updates to MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.